Pureos Bioventures

Ariceum is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers

BaseLaunch is the Basel area-based incubator and accelerator that helps scientists and entrepreneurs to launch exceptional biotech companies in Switzerland

Corlieve Therapeutics is a French biotech company, developing transformational therapies for neurological diseases The lead program is a treatment for drug resistant temporal lobe epilepsy leveraging innovative gene therapy approaches In June 2021, Corlieve was acquired by uniQure for up to € 250 million

Engimmune Therapeutics is a spin-off from ETH Zurich dedicated to the development of novel T-cell receptor (TCR)-based therapeutics in cancer

Eyevensys is a clinical-stage ophthalmology biotech company developing non-viral gene therapies for severe eye diseases using its ocular electro-transfection platform technology

Hummingbird Bioscience is a clinical-stage biopharmaceutical company focused on developing precision monoclonal antibodies against difficult targets for better therapies in different cancer indications

ImCheck Therapeutics is developing novel antibody therapeutics that target butyrophilin checkpoint molecules to activate immune cells for the treatment of cancer

Lava Therapeutics is developing bi- specific gamma- delta T-cell engagers for the treatment of hematological and solid cancers In March 2021, Lava went public at the NASDAQ (LVTX)

Mediar is a Boston-based preclinical stage biotechnology company developing antibody therapeutics targeting fibrotic mediators and myofibroblasts to treat fibrosis

MinervaX is a private, clinical stage biotech company pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS)

NovaGo Therapeutics is a Swiss start-up dedicated to the development of regenerative therapies for diseases in the eye and the central nervous system

River Renal is a clinical-stage company developing novel therapies for orphan renal diseases

Tridek-One is a spin-off from Inserm that develops immune checkpoint agonists for the treatment of autoimmune diseases

Vico Therapeutics is a Dutch biotech company developing anti-sense oligonucleotides for treating rare severe neurological disorders with high unmet medical need

We are driven by the quest for new and better medicines We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines

Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e g , Brolucizumab) Since 2002 he was a Board Member of the Swiss Biotech Association, the biotech industry organization of Switzerland which he led as President from 2013 to 2022 Dominik obtained his PhD in Molecular Biology from the University of Zurich

Klaus is a founding partner of Pureos and has been a venture capital investor since 2001, across different regions, companies stages and types Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management Bio-pharmaceutical companies that Klaus has invested in include AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm Before venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg (ZMBH)

Martin is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, binX Health, River Renal and SatoSea Oncology Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich

Veronica joined the Pureos Bioventures team as a Partner in 2022 She has been a founder CEO of Glycoera, a Zurich-based company with a glycoengineering platform for novel antibodies in autoimmune diseases, oncology and neurology She was also a co-founder and the CEO of LimmaTech Biologics, a spin-off of GlycoVaxyn to service GSK Before that, Veronica was in the executive team of GlycoVaxyn developing innovative vaccines for infectious diseases She was instrumental in the acquisition of the company by GSK in 2015 Veronica is a bioengineer with a PhD in life science from the EPFL Lausanne

Ximing joined the Pureos Bioventures team in 2018 Prior to Pureos, he was Post-Doc at the European Molecular Biology Laboratory in Heidelberg, Germany Ximing is currently BoD observer at Araris Biotech, Engimmune Therapeutics and Tridek-One Ximing obtained his PhD at the European Molecular Biology Laboratory and holds an MSc in Biology at ETH Zurich

Anne joined the Pureos Bioventures team in 2021 She has collected first venture capital experience as Analyst fellow at M Ventures, the corporate venture arm of Merck KGaA, in Amsterdam Prior to that, Anne was Post-Doc at the University of Basel Anne obtained her PhD in structural biology from the University of Basel and studied biochemistry and molecular biology at the University of Kiel and the University of Jena, in Germany, and at the University of York in the UK

Christian joined the Pureos Bioventures team in 2022 and has worked in the finance industry for over 20 years Prior to joining Pureos, Christian was Deputy CRO at responsAbility Investment AG and before this COO & CRO and member of the management board at QCAM Currency Asset Management AG Christian also held senior positions at Leonteq AG and Man Investments AG Christian obtained his Bachelor of Business Administration at the ZHAW and is a certified international investment analyst (CIIA) He is a lecturer at the Swiss Training Centre for Investment Professionals AZEK

Nina is Office Manager & Team Assistant at Pureos Partners After her studies of Applied Business Languages and International Management, Nina lived and worked for many years in Japan, China and the Philippines After her return to Switzerland, Nina had various management assistant roles in different industries Nina also teaches Yoga and bodytherapy techniques and joined Pureos in 2021

Dragan was CSO and co-founder of Covagen AG, a Swiss biotech company focusing on bispecific antibodies and antibody alternatives Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson acquired Covagen in 2014 Since 2015 Dragan is an independent advisor in pharmaceutical biotechnology, start-up coach at ETH Zurich and Innosuisse (Swiss Innovation Agency), board member and entrepreneur Dragan received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich

Ulf is co-founder and CEO of T-CURX He was also founder and CEO of NBE-Therapeutics, a Swiss biotech company developing antibody-drug conjugates (ADCs) for treating cancer patients NBE was acquired by Boehringer Ingelheim for up to USD 1 4 billion in 2021 Before that, Ulf was co-founder, start-up CEO and later CSO of 4-Antibody, an antibody discovery company, which was acquired by Agenus in 2014 Ulf is Vice-president and Board member of the Swiss Biotech Association and supports several biotechs as advisor and board member Ulf is a biochemist He obtained his PhD in Cell Biology from the Basel Institute for Immunology and a Diploma of Technology Entrepreneurship from the University of St Gallen

Roberto is CEO of Alentis Therapeutics and a physician-scientist and biotech entrepreneur who has advanced several assets to early clinical development He has strong translational medicine and strategic experience across rare diseases, fibrosis, immunology, and oncology Prior to Alentis, Roberto was part of the leadership team which built Black Diamond Therapeutics from inception through multiple financing rounds and to a NASDAQ IPO, and Bright Peak Therapeutics Prior to that he was heading rare diseases research at Roche Roberto holds a PhD from TU Dresden, Germany and an MD from University of Naples Frederico II, Italy

Lars brings more than 20 years of leadership experience in the development of several pharmaceutical products and innovative technologies Lars is Chief Technology Officer at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers Previously, Lars was VP and Strategic Product Lead at Bayer Before that Lars held several leadership roles at F Hoffmann-La Roche responsible for clinical supply planning, biologics technology and technical business development biologics Lars gained his PhD from the Max-Planck-Institute for Biochemistry, Munich, and Institute for Biochemistry at the University of Zürich; he also holds an executive MBA from the University of St Gallen, Switzerland

Omar is currently CMO at VectivBio, and was before that CMO and Head of Research and Development at Voyager Therapeutics Previous to that, he was the Global Head of Rare Diseases and Neuroscience Translational Medicine at Roche, practiced medicine at Boston Children’s Hospital and was Chief Resident at Harvard Medical School Dr Khwaja received his MD and PhD in Human Molecular Genetics from the University of Cambridge, UK He is a member of the Royal College of Physicians, serves as CMO for the Spinal Muscular Atrophy Foundation and is the Chair of the Scientific Advisory Board of the CDKL5 Forum